Ampio Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>AP</div>
AMPE -- USA Stock  

USD 1.70  0.04  2.30%

It looks as if Ampio Pharmaceuticals will continue to recover much faster as its share price surged up 19.77% today. The company's current daily volatility is 9.26 percent, with a beta of 0.28 and an alpha of 1.76 over DOW. While some of us are getting more passionate about pharmaceutical products, it makes sense to digest Ampio Pharmaceuticals in greater detail to make a better estimate of its volatility. We will evaluate why recent Ampio Pharmaceuticals price moves suggest a bounce in January.
Published over a month ago
View all stories for Ampio Pharmaceuticals | View All Stories
Is Ampio Pharmaceuticals (NYSEMKT:AMPE) a new disruptor?
This firm conducts business under Healthcare sector and is part of Biotechnology industry. Ampio Pharmaceuticals holds a performance score of 13 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.2775, which signifies not very significant fluctuations relative to the market. Let's try to break down what Ampio's beta means in this case. As returns on the market increase, Ampio Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Ampio Pharmaceuticals will be expected to be smaller as well. Although it is essential to pay attention to Ampio Pharmaceuticals historical returns, it is also good to be reasonable about what you can do with equity current trending patterns. Our philosophy towards foreseeing future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Ampio Pharmaceuticals expected return of 1.74 will be sustainable into the future, we have found twenty-one different technical indicators, which can help you to check if the expected returns are sustainable. Use Ampio Pharmaceuticals jensen alpha, as well as the relationship between the potential upside and skewness to analyze future returns on Ampio Pharmaceuticals.
Investing in Ampio Pharmaceuticals, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Ampio Pharmaceuticals along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Ampio Pharmaceuticals' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Ampio Pharmaceuticals in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Ampio Pharmaceuticals. Your research has to be compared to or analyzed against Ampio Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Ampio Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Ampio Pharmaceuticals.

How important is Ampio Pharmaceuticals's Liquidity

Ampio Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Ampio Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Ampio Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Ampio Pharmaceuticals's total debt and its cash.

How Ampio utilizes its cash?

To perform a cash flow analysis of Ampio Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Ampio Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Ampio Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Ampio Pharmaceuticals Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (13.84 Million)

Ampio Pharmaceuticals Correlation with Peers

Investors in Ampio can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Ampio Pharmaceuticals. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Ampio Pharmaceuticals and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Ampio is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Ampio for more details

A Deeper look at Ampio

Ampio Pharmaceuticals is dangerous given 1 month investment horizon. Ampio Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.19, which signifies that the company had 0.19% of return per unit of risk over the last month. Our standpoint towards foreseeing the risk of a stock is to use both market data as well as company specific technical data. We were able to break down and interpolate data for twenty-one different technical indicators, which can help you to evaluate if expected returns of 1.74% are justified by taking the suggested risk. Use Ampio Pharmaceuticals Mean Deviation of 6.06, risk adjusted performance of 0.2185, and Downside Deviation of 7.77 to evaluate company specific risk that cannot be diversified away.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Ampio Pharmaceuticals implied volatility may change after the surge

The standard deviation is down to 9.25 as of today. Ampio Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Ampio Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Ampio Pharmaceuticals volatility.

Our Final Perspective on Ampio Pharmaceuticals

Although some other firms under the biotechnology industry are still a bit expensive, Ampio Pharmaceuticals may offer a potential longer-term growth to shareholders. To conclude, as of the 26th of December 2020, we believe that at this point, Ampio Pharmaceuticals is dangerous with below average probability of financial unrest within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. Our primary 30 days buy-hold-sell recommendation on the firm is Cautious Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Ampio Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com